Show simple item record

dc.contributor.authorBeck-Engeser, G
dc.contributor.authorStocking, C
dc.contributor.authorJust, U
dc.contributor.authorAlbritton, L
dc.contributor.authorDexter, T Michael
dc.contributor.authorSpooncer, Elaine
dc.contributor.authorOstertag, W
dc.date.accessioned2010-06-11T10:48:39Z
dc.date.available2010-06-11T10:48:39Z
dc.date.issued1991
dc.identifier.citationRetroviral vectors related to the myeloproliferative sarcoma virus allow efficient expression in hematopoietic stem and precursor cell lines, but retroviral infection is reduced in more primitive cells. 1991, 2 (1):61-70 Hum. Gene Ther.en
dc.identifier.issn1043-0342
dc.identifier.pmid1863641
dc.identifier.doi10.1089/hum.1991.2.1-61
dc.identifier.urihttp://hdl.handle.net/10541/104684
dc.description.abstractRetroviral vectors are considered to be the most suited vehicles for somatic gene therapy with hematopoietic stem cells as targets. Retrovirus-mediated gene transfer into differentiation-restricted hematopoietic precursor (FDC-P1, FDC-P2) and multipotent progenitor (stem) cell lines (FDC-Pmix) is inefficient. Two cellular restrictions are involved. One is specific for stem but not precursor cells and is at the level of transcription. Due to a unique property of the transcriptional control region of the myeloproliferative sarcoma virus (MPSV), vectors derived from MPSV are not affected by this block. The second restriction occurs before proviral DNA synthesis and integration. This inhibition of effective viral infection depends on the state of differentiation, being more pronounced in multipotent clonogenic blast cells. This block to retroviral infection affects all retroviral vectors tested.
dc.language.isoenen
dc.subjectHaematopoietic Stem Cellsen
dc.subject.meshAnimals
dc.subject.meshCell Differentiation
dc.subject.meshCell Line
dc.subject.meshDNA, Viral
dc.subject.meshDefective Viruses
dc.subject.meshFibroblasts
dc.subject.meshGene Expression Regulation
dc.subject.meshGenetic Vectors
dc.subject.meshHematopoietic Stem Cells
dc.subject.meshMice
dc.subject.meshMoloney murine sarcoma virus
dc.subject.meshProviruses
dc.subject.meshReceptors, Virus
dc.subject.meshTranscription, Genetic
dc.subject.meshTransfection
dc.subject.meshTransformation, Genetic
dc.titleRetroviral vectors related to the myeloproliferative sarcoma virus allow efficient expression in hematopoietic stem and precursor cell lines, but retroviral infection is reduced in more primitive cells.en
dc.typeArticleen
dc.contributor.departmentHeinrich-Pette-Institut für Experimentelle Virologie und Immunologie, Universität Hamburg, Federal Republic of Germany.en
dc.identifier.journalHuman Gene Therapyen
html.description.abstractRetroviral vectors are considered to be the most suited vehicles for somatic gene therapy with hematopoietic stem cells as targets. Retrovirus-mediated gene transfer into differentiation-restricted hematopoietic precursor (FDC-P1, FDC-P2) and multipotent progenitor (stem) cell lines (FDC-Pmix) is inefficient. Two cellular restrictions are involved. One is specific for stem but not precursor cells and is at the level of transcription. Due to a unique property of the transcriptional control region of the myeloproliferative sarcoma virus (MPSV), vectors derived from MPSV are not affected by this block. The second restriction occurs before proviral DNA synthesis and integration. This inhibition of effective viral infection depends on the state of differentiation, being more pronounced in multipotent clonogenic blast cells. This block to retroviral infection affects all retroviral vectors tested.


This item appears in the following Collection(s)

Show simple item record